(Q28272666)

Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution

20 April 2017

1 reference

Human renin gene: structure and sequence analysis

20 April 2017

1 reference

Potent new inhibitors of human renin

20 April 2017

1 reference

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

20 April 2017

1 reference

Structure-based design of aliskiren, a novel orally effective renin inhibitor

20 April 2017

1 reference

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

20 April 2017

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

20 April 2017

1 reference

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

20 April 2017

1 reference

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

20 April 2017

1 reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

20 April 2017

1 reference

20 April 2017

1 reference

Robert Tigerstedt--scientist, educator, social activist, humanitarian.

21 January 2018

1 reference

STUDIES ON EXPERIMENTAL HYPERTENSION : I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA.

21 January 2018

1 reference

The existence of two forms of hypertensin

21 January 2018

1 reference

The amino acid sequence of hypertensin. II.

21 January 2018

1 reference

Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension

21 January 2018

1 reference

Captopril (SQ 14,225) (d-3-mercapto-2-methylpropanoyl-l-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent

21 January 2018

1 reference

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

21 January 2018

1 reference

21 January 2018

1 reference

Angiotensin II-generating enzymes

21 January 2018

1 reference

Mast cell chymase expression and mast cell phenotypes in human rejected kidneys

21 January 2018

1 reference

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients

21 January 2018

1 reference

Renin and Its Putative Receptor Remain Enigmas

21 January 2018

1 reference

Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system

21 January 2018

1 reference

Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients

21 January 2018

1 reference

Precipitation of the renin inhibitor ditekiren upon i.v. infusion; in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey

21 January 2018

1 reference

Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats

21 January 2018

1 reference

Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes

21 January 2018

1 reference

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

21 January 2018

1 reference

Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled

21 January 2018

1 reference

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

Prevalence of hypertension, its awareness and control in adult population in Japan.

21 January 2018

1 reference

Meta-analysis on the therapeutic state of hypertensive population in Japan: focusing on the impact of new diagnostic criteria of Japanese Guideline for the Management of Hypertension 2000.

21 January 2018

1 reference

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

21 January 2018

1 reference

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

21 January 2018

1 reference

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

21 January 2018

1 reference

Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators

21 January 2018

1 reference

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

21 January 2018

1 reference

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

Direct renin inhibition with aliskiren in hypertension and target organ damage

21 January 2018

1 reference

Blood pressure-independent effects in rats with human renin and angiotensinogen genes.

21 January 2018

1 reference

Complement activation in angiotensin II-induced organ damage

21 January 2018

1 reference

Letter by Fisher and Johns regarding article, "Variable platelet response to aspirin and clopidogrel in atherothrombotic disease".

21 January 2018

1 reference

Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.

21 January 2018

1 reference

Letter by Testa et al regarding article, "Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization".

21 January 2018

1 reference

ESH-ESC Guidelines for the Management of Hypertension

21 January 2018

1 reference

Clinical Experience With Angiotensin II Receptor Antagonists

21 January 2018

1 reference

Functional and biochemical analysis of angiotensin II-forming pathways in the human heart

31 March 2020

1 reference

Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure

31 March 2020

1 reference

Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy

31 March 2020

1 reference

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

31 March 2020

1 reference

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

31 March 2020

1 reference

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

31 March 2020

1 reference

Prorenin and the (pro)renin receptor--an update

31 March 2020

1 reference

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

31 March 2020

1 reference

Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin

31 March 2020

1 reference

Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets

31 March 2020

1 reference

Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans

31 March 2020

1 reference

Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension

31 March 2020

1 reference

Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys

31 March 2020

1 reference

Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study

31 March 2020

1 reference

Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension

31 March 2020

1 reference

Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects

31 March 2020

1 reference

Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment

31 March 2020

1 reference

Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus

31 March 2020

1 reference

Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril

31 March 2020

1 reference

Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers

31 March 2020

1 reference